Literature DB >> 31337628

Severe presentation of antibody-negative, postinfectious steroid-responsive encephalitis and atonic bladder after herpes simplex encephalitis.

Luay Mrad1, Argirios Moustakas1, Robert Fuino1, Waqar Waheed1.   

Abstract

A 75-year-old woman presented with new onset of confusion, intense episodic dizziness and formed visual hallucinations. Herpes simplex encephalitis and non-convulsive temporal lobe seizures were confirmed with cerebrospinal fluid (CSF) and electroencephalography testing. In addition, her hospital course was complicated by syndrome of inappropriate antidiuretic hormone secretion and atonic bladder contributing to an episode of urinary tract infection. After completing 3 weeks of acyclovir treatment, the patient became obtunded with right arm choreiform movements and persistent inflammatory CSF findings not attributable to persistent herpes simplex virus infection or other confounding factors. The patient responded to steroid treatment. Repeated autoimmune and paraneoplastic evaluations were negative. Both clinical (cognitive testing and atonic bladder) and CSF inflammatory finding improved in the follow-up period. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  clinical neurophysiology; epilepsy and seizures; immunology; neurology

Mesh:

Substances:

Year:  2019        PMID: 31337628      PMCID: PMC6663208          DOI: 10.1136/bcr-2019-230005

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  25 in total

1.  Experimental herpes simplex virus encephalitis: a combination therapy of acyclovir and glucocorticoids reduces long-term magnetic resonance imaging abnormalities.

Authors:  Uta K Meyding-Lamadé; Christoph Oberlinner; Philipp R Rau; Sonja Seyfer; Sabine Heiland; Johann Sellner; Brigitte T Wildemann; Wolfram R Lamadé
Journal:  J Neurovirol       Date:  2003-02       Impact factor: 2.643

2.  Acyclovir resistance in herpes simplex virus type I encephalitis: a case report.

Authors:  Andreas Sauerbrei
Journal:  J Neurovirol       Date:  2017-06-21       Impact factor: 2.643

3.  Localizing value of epileptic visual auras.

Authors:  C G Bien; F O Benninger; H Urbach; J Schramm; M Kurthen; C E Elger
Journal:  Brain       Date:  2000-02       Impact factor: 13.501

Review 4.  Herpes simplex virus drug-resistance: new mutations and insights.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

5.  Quantitation of herpes simplex virus type 1 DNA in cells of cerebrospinal fluid of patients with herpes simplex virus encephalitis.

Authors:  B Wildemann; K Ehrhart; B Storch-Hagenlocher; U Meyding-Lamadé; S Steinvorth; W Hacke; J Haas
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

6.  Parainfectious encephalomyeloradiculitis associated with herpes simplex virus 1 DNA in cerebrospinal fluid.

Authors:  T Kusuhara; M Nakajima; H Inoue; M Takahashi; T Yamada
Journal:  Clin Infect Dis       Date:  2002-04-04       Impact factor: 9.079

Review 7.  Innate immune response during herpes simplex virus encephalitis and development of immunomodulatory strategies.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Rev Med Virol       Date:  2015-07-23       Impact factor: 6.989

8.  Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization.

Authors:  Růzena Stránská; Rob Schuurman; Elske Nienhuis; Irma W Goedegebuure; Merjo Polman; Jan F Weel; Pauline M Wertheim-Van Dillen; Ron J M Berkhout; Anton M van Loon
Journal:  J Clin Virol       Date:  2005-01       Impact factor: 3.168

9.  Magnetic resonance and diffusion-weighted imaging findings of herpes simplex encephalitis.

Authors:  Hatice Gul Hatipoglu; Bulent Sakman; Enis Yuksel
Journal:  Herpes       Date:  2008-10

10.  Herpes simplex virus type-1 meningoencephalitis showing disseminated cortical lesions.

Authors:  Kosuke Naito; Takao Hashimoto; Shu-ichi Ikeda
Journal:  Intern Med       Date:  2007-06-01       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.